JP5964815B2 - 固体担体からの放出制御薬物 - Google Patents

固体担体からの放出制御薬物 Download PDF

Info

Publication number
JP5964815B2
JP5964815B2 JP2013509279A JP2013509279A JP5964815B2 JP 5964815 B2 JP5964815 B2 JP 5964815B2 JP 2013509279 A JP2013509279 A JP 2013509279A JP 2013509279 A JP2013509279 A JP 2013509279A JP 5964815 B2 JP5964815 B2 JP 5964815B2
Authority
JP
Japan
Prior art keywords
solid support
optionally substituted
drug
group
coupled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013509279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525080A5 (enExample
JP2013525080A (ja
Inventor
ギャリー アシュレー
ギャリー アシュレー
ダニエル ブイ． サンティ
ダニエル ブイ． サンティ
Original Assignee
プロリンクス リミテッド ライアビリティ カンパニー
プロリンクス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロリンクス リミテッド ライアビリティ カンパニー, プロリンクス リミテッド ライアビリティ カンパニー filed Critical プロリンクス リミテッド ライアビリティ カンパニー
Publication of JP2013525080A publication Critical patent/JP2013525080A/ja
Publication of JP2013525080A5 publication Critical patent/JP2013525080A5/ja
Application granted granted Critical
Publication of JP5964815B2 publication Critical patent/JP5964815B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6953—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a fibre, a textile, a slab or a sheet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
JP2013509279A 2010-05-05 2011-05-05 固体担体からの放出制御薬物 Active JP5964815B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33174210P 2010-05-05 2010-05-05
US61/331,742 2010-05-05
PCT/US2011/035422 WO2011140392A1 (en) 2010-05-05 2011-05-05 Controlled drug release from solid supports

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016050380A Division JP6250723B2 (ja) 2010-05-05 2016-03-15 固体担体からの放出制御薬物

Publications (3)

Publication Number Publication Date
JP2013525080A JP2013525080A (ja) 2013-06-20
JP2013525080A5 JP2013525080A5 (enExample) 2014-06-19
JP5964815B2 true JP5964815B2 (ja) 2016-08-03

Family

ID=44904089

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013509279A Active JP5964815B2 (ja) 2010-05-05 2011-05-05 固体担体からの放出制御薬物
JP2016050380A Active JP6250723B2 (ja) 2010-05-05 2016-03-15 固体担体からの放出制御薬物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016050380A Active JP6250723B2 (ja) 2010-05-05 2016-03-15 固体担体からの放出制御薬物

Country Status (6)

Country Link
US (1) US8946405B2 (enExample)
EP (1) EP2566334B1 (enExample)
JP (2) JP5964815B2 (enExample)
CN (1) CN103025164B (enExample)
DK (1) DK2566334T3 (enExample)
WO (1) WO2011140392A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP2729179B1 (en) 2011-06-06 2020-09-23 Starpharma Pty Ltd Macromolecules
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
AU2012304337B2 (en) 2011-09-07 2015-05-07 Prolynx Llc Hydrogels with biodegradable crosslinking
EP2850201A4 (en) * 2012-05-11 2016-08-31 Alexander Krantz Site-specific labeling and targeted administration of proteins for the treatment of cancer
EP2925256A4 (en) * 2013-01-22 2016-08-17 Prolynx Llc SEALANTS HAVING CONTROLLED DEGRADATION
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
CN106232131A (zh) * 2013-10-22 2016-12-14 普洛林克斯有限责任公司 生长抑素和其类似物的结合物
IL290330B2 (en) * 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
IL259829B2 (en) 2016-01-08 2023-03-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr–c binding
CN108472380B (zh) 2016-01-08 2022-03-01 阿森迪斯药物生长障碍股份有限公司 具有增加的nep稳定性的控制释放cnp激动剂
WO2017118698A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
WO2017118703A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
BR112018017091A2 (pt) 2016-03-01 2019-01-02 Ascendis Pharma Bone Diseases As profármacos de pth
CN109414469A (zh) * 2016-03-16 2019-03-01 普罗林科斯有限责任公司 艾塞那肽类似物的缓释偶联物
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
US11590207B2 (en) 2016-09-29 2023-02-28 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release PTH compound
KR20230170810A (ko) 2016-09-29 2023-12-19 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
EP4223309A1 (en) 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
US12453778B2 (en) 2016-09-29 2025-10-28 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US11965041B2 (en) 2017-09-19 2024-04-23 Technische Universitaet Muenchen N-methylated cyclic peptides and their prodrugs
WO2019058367A1 (en) * 2017-09-19 2019-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. LIPOPHILIC PRODRUGS BASED ON PEPTIDES
WO2019140266A1 (en) 2018-01-12 2019-07-18 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification
US11213596B2 (en) 2018-03-12 2022-01-04 Boston Scientific Scimed, Inc. Radiocontrast agents, scavenging methods, and scavenging system
US20210008168A1 (en) 2018-03-28 2021-01-14 Ascendis Pharma A/S Conjugates
CA3093722A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma Oncology Division A/S Il-2 conjugates
DK3793587T3 (da) 2018-05-18 2025-07-21 Ascendis Pharma Bone Diseases As Startdosis af pth-konjugater
BR112021000658A2 (pt) 2018-07-19 2021-04-13 Starpharma Pty Ltd Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
CA3114329A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
US20210330798A1 (en) 2018-09-26 2021-10-28 Ascendis Pharma A/S Treatment of infections
AU2019348440B2 (en) 2018-09-26 2024-09-12 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020141222A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Sustained local drug levels for innate immune agonists
AU2020205029A1 (en) 2019-01-04 2021-06-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
US20220054477A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
JP2022516308A (ja) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス パターン認識受容体アゴニストのコンジュゲート
MY209748A (en) 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
CN114286693A (zh) * 2019-04-05 2022-04-05 普罗林科斯有限责任公司 改良偶联接头
JP7608360B2 (ja) * 2019-04-26 2025-01-06 プロリンクス エルエルシー 徐放性サイトカインコンジュゲート
AU2020295724A1 (en) 2019-06-21 2021-12-02 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
KR20220024690A (ko) * 2019-06-21 2022-03-03 아센디스 파마 에이에스 π 전자쌍 공여 헤테로방향족 질소 포함 화합물의 컨쥬게이트
EP4037715A4 (en) * 2019-09-30 2023-12-13 OD Therapeutics Limited Protein-macromolecule conjugates and methods of use thereof
IL294357A (en) 2020-01-13 2022-08-01 Ascendis Pharma Bone Diseases As Hypoparathyroidism treatment
CA3175974A1 (en) 2020-05-04 2021-11-11 Oliver Boris Stauch Hydrogel irradiation
US12428461B2 (en) 2020-06-03 2025-09-30 Ascendis Pharma Oncology Division A/S Treating cancer with a conjugate comprising an IL-2 moiety
JP2023540701A (ja) 2020-08-28 2023-09-26 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス グリコシル化ｉｌ－２タンパク質及びその使用
US20230364199A1 (en) 2020-09-28 2023-11-16 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
EP4314035A1 (en) 2021-04-01 2024-02-07 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
AU2022350937A1 (en) 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
WO2023069510A1 (en) * 2021-10-19 2023-04-27 The United States Government As Represented By The Department Of Veterans Affairs Cannabinoid compositions for gastroesophageal disorders
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
EP4448011A2 (en) 2021-12-13 2024-10-23 Ascendis Pharma Oncology Division A/S Cancer treatments with tlr7/8 agonists
JP2025522281A (ja) 2022-05-23 2025-07-15 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐ化合物の液体医薬製剤
CN114874624B (zh) * 2022-05-27 2023-04-07 深圳市博致远科技有限公司 一种导热吸波室温固化硅橡胶产品及其制备方法
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
AU2024233842A1 (en) 2023-03-06 2025-09-04 Ascendis Pharma A/S Multi-albumin binding compounds
IL323019A (en) 2023-03-06 2025-10-01 Ascendis Pharma As Drug compounds with an albumin-binding moiety
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
AU2024270185A1 (en) 2023-05-09 2025-11-06 Ascendis Pharma Oncology Division A/S Novel cancer treatments with il-2 conjugates
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
WO2025208117A1 (en) * 2024-03-29 2025-10-02 Maha Therapeutics, Inc. Cleavable ester compounds and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3563968A (en) 1967-10-03 1971-02-16 Gaf Corp Process for the preparation of functional polymers from n-vinyl pyrrolidone
US4265233A (en) 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
US4769445A (en) 1985-03-04 1988-09-06 Pennwalt Corporation Process for the solid phase synthesis of peptides which contain sulfated tyrosine
US6033719A (en) 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
AU7522601A (en) 2000-06-02 2001-12-11 Eidgenoess Tech Hochschule Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7264822B2 (en) * 2002-04-03 2007-09-04 Poly-Med, Inc. Conjugated drug-polymer coated stent
US7647099B2 (en) 2002-04-29 2010-01-12 Rocky Mountain Biosystems, Inc. Controlled release transdermal drug delivery
US7732535B2 (en) 2002-09-05 2010-06-08 Advanced Cardiovascular Systems, Inc. Coating for controlled release of drugs from implantable medical devices
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
US20100029646A1 (en) 2006-12-11 2010-02-04 Topo Target A/S Prodrugs of diphenyl ox-indol-2-one compounds
US7863387B2 (en) 2007-10-25 2011-01-04 Boston Scientific Scimed, Inc. Dehydrofluorination and surface modification of fluoropolymers for drug delivery applications
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
EP2571496A4 (en) * 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates

Also Published As

Publication number Publication date
US8946405B2 (en) 2015-02-03
JP6250723B2 (ja) 2017-12-20
DK2566334T3 (en) 2018-07-23
EP2566334A1 (en) 2013-03-13
CN103025164B (zh) 2017-03-08
JP2013525080A (ja) 2013-06-20
US20130123487A1 (en) 2013-05-16
CN103025164A (zh) 2013-04-03
JP2016166204A (ja) 2016-09-15
EP2566334B1 (en) 2018-04-18
WO2011140392A1 (en) 2011-11-10
EP2566334A4 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
JP6250723B2 (ja) 固体担体からの放出制御薬物
CA2786794C (en) Aromatic polymeric cascade prodrug linker reagent
US10456478B2 (en) Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
CN119970617A (zh) 改良偶联接头
US8703907B2 (en) Controlled drug release from dendrimers
JP2003503370A (ja) 核酸を細胞に導入するための配合剤
CA2885169A1 (en) Diagnosis, prevention and treatment of diseases of the joint
Ranucci et al. Polyamidoamines: Versatile bioactive polymers with potential for biotechnological applications
US20200268658A1 (en) Degradable hydrogel under physiological conditions
KR20220074897A (ko) 단백질-거대분자 접합체 및 이의 사용 방법
WO2014152451A2 (en) Compositions and methods for controlled localized delivery of bone forming therapeutic agents
Zhao et al. Oligoglycine and fluoropolymer functionalized enzyme-responsive gene delivery surface for rapid in situ endothelialization of vascular grafts
Jain et al. Thiolated chitosan as an improved bioadhesive polymer in drug delivery
US10195284B2 (en) Compositions and methods for controlled localized delivery of bone forming therapeutic agents
RU2845911C1 (ru) Конъюгаты белок-макромолекула и способы их применения
Warnock Development of N-terminal targeting ligands for protein-material conjugation
US20230405136A1 (en) New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration
HK1206378B (en) Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
HK1199709B (en) Hydrogels with biodegradable crosslinking

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160630

R150 Certificate of patent or registration of utility model

Ref document number: 5964815

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250